Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label nivolumab monotherapy in relapsed or refractory DLBCL after ASCT failure or in ASCT-ineligible patients
NL-OMON40237Phase 2Active, not recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Aug 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab in diffuse large B-cell lymphoma (DLBCL) and transformed lymphoma, sponsored by Bristol Myers Squibb. Primary endpoint: Objective response rate. Started Aug 2014; status: active, not recruiting.
02
Drugs
03
Conditions
diffuse large B-cell lymphoma (DLBCL)transformed lymphoma
Beyond the preview
Go deeper on NL-OMON40237.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40237.